Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Total Debt (2022 - 2025)

UroGen Pharma (URGN) has disclosed Total Debt for 4 consecutive years, with $122.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Debt changed 0.39% year-over-year to $122.2 million, compared with a TTM value of $122.2 million through Dec 2025, changed 0.39%, and an annual FY2025 reading of $122.2 million, changed 0.39% over the prior year.
  • Total Debt was $122.2 million for Q4 2025 at UroGen Pharma, roughly flat from $122.1 million in the prior quarter.
  • Across five years, Total Debt topped out at $122.5 million in Q2 2025 and bottomed at $70.8 million in Q1 2022.
  • Average Total Debt over 4 years is $102.0 million, with a median of $98.4 million recorded in 2023.
  • The sharpest move saw Total Debt soared 38.34% in 2023, then dropped 0.49% in 2024.
  • Year by year, Total Debt stood at $97.5 million in 2022, then rose by 1.04% to $98.6 million in 2023, then rose by 23.52% to $121.7 million in 2024, then increased by 0.39% to $122.2 million in 2025.
  • Business Quant data shows Total Debt for URGN at $122.2 million in Q4 2025, $122.1 million in Q3 2025, and $122.5 million in Q2 2025.